ClinicalTrials.gg
Status unknownNCT02225886FeVitCUpdated Feb 24, 2020

Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients

A Phase 4 interventional study of Ascorbic Acid in Anaemia Response to the Treatment, Peripheral Iron Indices and Oxalemia, sponsored by Anemia Working Group Romania. Status unknown at 1 site in Romania. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-02-24.

Sponsored by Anemia Working Group Romania · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The administration of ascorbic acid seemed to increase the iron available for erythropoiesis, thus improving the anemia response to the treatment.

The investigators therefore aimed to evaluate the effects of intravenous ascorbic acid administration in hemodialysed patients with iron overload.

Read the detailed description

Renal anemia is a complex condition in which chronic inflammation, among other factors, can change the iron distribution by locking it in deposits, and also, iron metabolism parameters. Thus, is hard to separate the iron functional deficit from overload.

The ascorbic acid is a hydrosoluble vitamin capable of reduction and hydrolysis. As a reduction agent, the ascorbic acid supports the transformation of ferric iron to ferrous iron. For instance, the ascorbic acid can increase digestive absorption and taking over the iron without transferrin, helps iron release from ferritin and hemosiderin and delays ferritin conversion to hemosiderin; therefore, the administration of ascorbic acid can increase the quantity of iron available for erythropoiesis by realising it from the deposits.

Consequently, the antioxidant function of ascorbic acid can increase the red cells' lifetime, reducing the inflammation and improving erythropoietin response Following these premises, recent studies have examined the effect of administrating ascorbic acid to hemodialysed patients with erythropoiesis stimulating agents (ESA) hyporesponsiveness anemia and functional deficit or iron overload markers. The results of administering ascorbic acid revealed an increased level of hemoglobin and transferrin saturation (TSAT) combined with the decrease of ESA doses. The major limitations of these studies are the short amount of time for observation (\<6months) and the limited number of participants which hampered neither the complete evaluation of the goals, nor the adverse effects of supplementary administration of vitamin C.

Until now, the Clinical practice guidelines of Kidney Disease do not recommend currently using of high doses of vitamin C, considering the risk of a high level of oxalemia and the limited information about the benefits. Considering this background, we intended to evaluate the benefits of intravenous administration of ascorbic acid in hemodialysed patients with iron balance markers suggestive for iron overload.

02

Conditions studied

  • Anaemia Response to the Treatment
  • Peripheral Iron Indices
  • Oxalemia

Keywords

  • Renal anaemia
  • Intravenous ascorbic acid
  • Intravenous iron administration
03

In context

Lead sponsor

Anemia Working Group Romania is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age above 18 years old
  • At least 6 months on hemodialysis at the time of randomization;
  • Kt/V≥1.2;
  • average of the last three serum ferritin levels > 500 ng/mL AND
  • Average of the last three TSAT levels > 20% and increasing
  • ERI in the 4th quartile of the group

Exclusion criteria

Exclusion Criteria:

  • Active bleeding or other cause of anemia
  • Serum level of intact parathyroid hormone (iPTH)>800 pg/mL
  • Actual neoplasia
  • , or C infections
  • Significant inflammation (CRP>12mg/L) or acute infection
  • Venous central catheter
  • Severe hepatic, cardiovascular, psychic disease or other severe comorbidities
  • Moderate or severe malnutrition
  • Blood transfusions in the 2 months prior to screening
  • Pregnancy or breastfeeding
  • Inclusion in another clinical trial in the past month
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Ascorbic acid

    Patients will receive a 300 mg intravenous ascorbic acid, 3 times a week, postdialysis, except for the dialysis sessions when iv iron is administered.

    Drug: Ascorbic Acid

  • Placebo comparator
    Control group

    Patients will receive 100 mL saline solution, 3 times a week, with associated medication, except but the dialysis sessions when iv iron is administered.

    Drug: Ascorbic Acid

Interventions

  • 300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered

06

What researchers measure

Primary outcomes

  1. Variation of erythropoetin resistance index (ERI)

    Erythropoietin resistance index: the dose of ESA divided by the level of Hb - will be calculated monthly.

    Time frame: 12 months

Secondary outcomes

  1. Percentage of patients with Hb in the target range

    Percentage of patients with stable the hemoglobin in the target range (10.5-12g/dL), without any change in the weekly dose of ESA

    Time frame: 12 months

  2. Changes in ESA dose

    The number of reductions or increases in the ESA dose during the study

    Time frame: 12 months

  3. Variation in ESA dose

    The difference between the actual ESA dose and the one at baseline will be calculated monthly.

    Time frame: 12 months

  4. Variation of iron dose

    The difference between the actual iron dose and the one at baseline will be calculated monthly.

    Time frame: 12 months

  5. Percentage of patients with hemoglobin within target

    Percentage of patients with 10\<Hb\<12.1 g/dL will be calculated monthly.

    Time frame: 12 months

  6. Percentage of patients with target iron status

    Percentage of patients with 100\<serum ferritin\<800 ng/mL and 19\<transferrin saturation\<51% will be calculated monthly.

    Time frame: 12 months

  7. Variation of serum hepcidin

    Variation of serum hepcidin will be calculated every 3 months

    Time frame: 12 months

  8. Oxalemia

    Serum oxalate level will be calculated every 3 months

    Time frame: 12 months

  9. Local and general tolerance to vitamin C

    Local and general tolerance to vitamin C will be evaluated monthly

    Time frame: 12 months

  10. Adverse events

    Adverse events will be evaluated monthly

    Time frame: 12 months

  11. The number of withdrawals and dropouts

    The number of withdrawals and dropouts will be calculated monthly

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • "Nefrolab" Dialysis Center
    Slatina, Romania
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Publication

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: 24 months

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Mar 2023, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2014
First posted
Aug 26, 2014
StartActual
Feb 1, 2020
Primary completionEst.
Mar 2023
CompletionEst.
Dec 2023
Last update
Feb 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02225886
Lead sponsor
Anemia Working Group Romania
Responsible party
Sponsor
First posted
Aug 26, 2014
Start date
Feb 1, 2020
Primary completion
Mar 2023 (estimated)
Completion
Dec 2023 (estimated)
Last update
Feb 24, 2020

Study contacts

Liliana Garneata, MD, PhD
Contact
liliana.garneata@gmail.com
+40722619358
Tudor Simionescu, MD PhD
Contact
tudorsimi@yahoo.com
+40732161766
Gabriel Mircescu, Professor
study chair · Anemia Working Group Romania
Liliana Garneata, MD, PhD
study director · Anemia Workiing Group Romania
Tudor Simionescu, MD, PhD
principal investigator · "Carol Davila" Teaching Hospital of Nephrology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion